乙型肝炎核心相关抗原对接受核苷(酸)类似物治疗患者肝细胞癌发生率的影响
这项回顾性队列研究纳入1268例接受核苷(酸)类似物治疗超过1年的慢性乙型肝炎患者,在基线和1年时检测血清HBcrAg和HBsAg。中位随访8.9年,113例(8.9%)发生肝细胞癌(10.3/1000人年)。持续高HBcrAg水平与HCC风险升高相关,即使长期NA治疗维持病毒抑制。
要点
- 基线及治疗1年HBcrAg与HBsAg可预测NA治疗患者的HCC发生。
- HBeAg阳性组1年HBcrAg≥4.9 log U/mL与HCC显著相关(P=0.017)。
- HBeAg阴性组1年HBcrAg≥4.4 log U/mL与HCC显著相关(P=4.30×10-5)。
核心结论
- 持续高治疗中HBcrAg水平的患者尽管长期NA治疗维持病毒抑制,仍更可能发生HCC。
研究设计与样本
- 回顾性队列研究,纳入1268例接受核苷(酸)类似物治疗超过1年的患者,基线和1年检测血清HBcrAg和HBsAg。
主要发现
- 中位随访8.9年,113例(8.9%)发生HCC,发生率为10.3/1000人年。
- 1年时高治疗中HBcrAg水平与HCC显著相关:HBeAg阳性队列P=0.017(cut-off 4.9 log U/mL),HBeAg阴性队列P=4.30×10-5(cut-off 4.4 log U/mL)。
- 多变量Cox回归分析中,持续高治疗中HBcrAg水平者HCC风险高于低HBcrAg水平者:HBeAg阳性队列HR 6.15(95%CI 1.89-20.0,P=0.003);HBeAg阴性队列HR 2.54(95%CI 1.40-4.60,P=0.002)。
- 无酒精滥用患者的亚组分析结果相似。
关键数值与推荐
- HBeAg阳性队列1年HBcrAg cut-off值为4.9 log U/mL。
- HBeAg阴性队列1年HBcrAg cut-off值为4.4 log U/mL。
- HBeAg阳性队列持续高HBcrAg者HCC风险HR 6.15(95%CI 1.89-20.0,P=0.003)。
- HBeAg阴性队列持续高HBcrAg者HCC风险HR 2.54(95%CI 1.40-4.60,P=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis B virus (HBV) infection is an aetiologic factor for hepatocellular carcinoma (HCC). Baseline HBV DNA is a known independent predictor of HCC, and the serum hepatitis B core-related antigen (HBcrAg) level corresponds to intrahepatic covalently closed circular DNA. AIM: To investigate whether the baseline and on-treatment serum HBcrAg levels can predict HCC incidence in patients with chronic hepatitis B following nucleos(t)ide analogue (NA) therapy. METHODS: This retrospective cohort study included 1268 patients treated with NAs for >1 year. In all patients, serum HBcrAg and hepatitis B surface antigen levels were measured at baseline and 1 year. RESULTS: During a median follow-up of 8.9 years, 113 patients (8.9%) developed HCC (10.3/1000 person-years). These patients were stratified by baseline hepatitis B e-antigen (HBeAg) status into HBeAg+ and HBeAg- cohorts. High on-treatment HBcrAg levels at 1 year were found to associate significantly with HCC (HBeAg+ cohort: P = 0.017; HBeAg- cohort: P = 4.30 × 10-5 ; cut-off values: 4.9 log U/mL and 4.4 log U/mL, respectively). In a multivariate Cox regression analysis, patients with persistently high on-treatment HBcrAg levels had a higher risk of HCC than those with low HBcrAg levels (HBeAg+: hazard ratio [HR], 6.15, 95% confidence interval [CI]: 1.89-20.0, P = 0.003; HBeAg- cohort: HR, 2.54, 95% CI: 1.40-4.60; P = 0.002). A sub-analysis of patients without alcoholism yielded similar findings. CONCLUSIONS: Patients with persistently high on-treatment HBcrAg levels were more likely to develop HCC despite sustained viral suppression via long-term NA treatment.
引用
- Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2019. PMID: 30663078. doi:10.1111/apt.15108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。